Correction to 'BAP18 coactivates androgen receptor action and promotes prostate cancer progression'.

In Figure 5B of the above article (1), the two α-MLL1 panels have inadvertently been duplicated during figure assembly. The panel α-MLL1 Input is correct but the panel α-MLL1 IP;WB needs to be replaced. The authors have recovered the original immunoblots and provide a corrected figure below.

Figure 5.

BAP18 interacts with MLL1 subcomplex. (A) BAP18, AR, MLL1 and MOF are recruited together to cis-regulatory elements of PSA in the absence or presence of DHT. ChIP/re-ChIP experiments were performed using specific antibodies against BAP18, AR, MLL1, MOF or IgG as indicated. DNA eluted from unprecipitated chromatin was used as input. Chromatin samples were analyzed by gel electrophoresis. (B) 22Rv1 cells were treated with shBAP18 or shCtrl, and immunoprecipitated using anti-AR antibodies or IgG. Precipitated protein complex were analyzed byWestern blotting with antibodies as indicated. Input represents 5% of the total cell extract used for each immunoprecipitation. (C and D) LNCaP cells were incubated with or without DHT, transfected with BAP18 expression plasmids or siRNA against BAP18 (siBAP18). Immunoprecipitate generated with anti-FLAG or anti-AR antibody was subjected to Western blotting with the indicated antibodies. (E) AR-dependent transactivation requires BAP18, MLL1 or Ash2L in cells. Cos-7 cells were co-transfected with the AR together with BAP18, MLL1, Ash2L or MOF expression plasmid as indicated. The total amount of the transfected DNA was kept constant with the empty vector.